Department of Veterans Affairs Purchases Six ReWalk Robotics Exoskeleton Systems for National Multi-Center Clinical Trial
Four-Year Study Will
Assess Impacts of Exoskeleton Use in Home/Community Setting on Patient Health
& Well-Being
YOKNEAM
ILIT, Israel and MARLBOROUGH, MA-- ReWalk Robotics
Ltd. (Nasdaq: RWLK) (“ReWalk”), the leading global exoskeleton developer and manufacturer, announced today
the Department of Veterans Affairs (“VA”) awarded a delivery order to Veterans
Healthcare Supply Solutions (VHSS), the Service Disabled Veteran Owned Small
Business (SDVOSB) authorized distributor of ReWalk Robotics for the
exoskeleton systems to support a first-of-its-kind national study.
The
Department of Veterans Affairs is the largest single healthcare provider to
persons with Spinal Cord Injury (SCI) in the United States. This VA national research study seeks to examine the impact of exoskeletal-assisted
walking in the home and community setting on quality of life and health
outcomes in eligible Veterans with spinal cord injury. The study is planned to
be conducted at 10 VA Medical Centers with Spinal Cord Injury Services across
the United States. This is the first study in the United States to examine the impact
of exoskeleton use in a home or daily life setting.
“The Department of Veterans Affairs has led
the way in its examination of the impact of exoskeleton use and the correlated
health benefits experienced by patients,” said ReWalk CEO Larry Jasinski. “We are excited they are continuing to build more quality
research data that has the potential to demonstrate the value of home use of an
exoskeleton.”
For this study, ReWalk Robotics, Inc. has already shipped
six of these systems for the clinical trial.
ReWalk is the only FDA cleared exoskeleton technology for individuals
with spinal cord injury. ReWalk has
Class II FDA clearances for exoskeleton use in the rehabilitation and personal
setting, with the latter intended for home and community use.
###
About
ReWalk Personal 6.0
ReWalk Personal 6.0 is a wearable robotic exoskeleton that provides
powered hip and knee motion to enable individuals with spinal cord injury to
stand upright and walk. The system provides user-initiated mobility through the
integration of a wearable brace support, a computer-based control system and
motion sensors. The system allows independent, controlled walking while
mimicking the natural gait patterns of the legs. The ReWalk device is the most studied
exoskeleton in the industry. Studies
have identified a number of health benefits including: improved
bladder and bowel function, improved mental health, improved sleep, reduced
fatigue, decreased body fat, decreased pain and improved posture and balance.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and
markets wearable robotic exoskeletons for individuals with spinal cord injury. Our mission is to fundamentally change the
quality of life for individuals with lower limb disability through the creation
and development of market leading robotic technologies. Founded in 2001, ReWalk has offices in the US,
Israel, and Germany. For more information on the ReWalk systems, please
visit http://www.rewalk.com.
ReWalk® is a registered trademark of ReWalk Robotics
Ltd. in Israel.
Forward Looking Statements
In addition to historical information, this press
release contains forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995, Section 27A of the U.S.
Securities Act of 1933, and Section 21E of the U.S. Securities Exchange
Act of 1934. Such forward-looking statements may include projections regarding
ReWalk’s future performance and, in some cases, may be identified by words like
“anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,”
“seek” and similar terms or phrases. The forward-looking statements contained
in this press release are based on management’s current expectations, which are
subject to uncertainty, risks and changes in circumstances that are difficult
to predict and many of which are outside of ReWalk’s control. Important factors
that could cause ReWalk’s actual results to differ materially from those
indicated in the forward-looking statements include, among others: ReWalk’s
expectations regarding future growth, including its ability to increase sales
in its existing geographic markets and to expand to new markets; ReWalk’s
ability to maintain and grow its reputation and the market acceptance of our
products; ReWalk’s ability to achieve reimbursement from third-party payors for
our products; ReWalk’s expectations as to its clinical research program and
clinical results; ReWalk’s ability to improve its products and develop new
products; ReWalk’s ability to maintain adequate protection of its
intellectual property and to avoid violation of the intellectual property rights
of others; ReWalk’s ability to gain and maintain regulatory approvals; ReWalk’s
ability to maintain relationships with existing customers and develop
relationships with new customers; and other factors discussed under the heading
“Risk Factors” in ReWalk’s Annual Report
on Form 20-F for the year ended December 31, 2014 filed with
the U.S. Securities and Exchange Commission on February 27, 2015 and other
documents subsequently filed with or furnished to the U.S. Securities and
Exchange Commission. Any forward-looking statement made in this press release
speaks only as of the date hereof. Factors or events that could cause ReWalk’s
actual results to differ from the statements contained herein may emerge from
time to time, and it is not possible for ReWalk to predict all of them. Except
as required by law, ReWalk undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information, future
developments or otherwise.
Media
Contact:
Jennifer Wlach
202-261-4000
Investor
Relations Contact:
Lisa M. Wilson
In-Site
Communications, Inc.
917-543-9932